Harold J. Burstein, MD, PhD, and Lisa A. Carey, MD, on Innovations in Triple-Negative Breast Cancer

2014 San Antonio Breast Cancer Symposium
Tweet this page

Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute and Lisa Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discuss:

  • The TNT trial comparing docetaxel to carboplatin
  • The CALGB trial on response rates after neoadjuvant chemo with or without carboplatin or bevacizumab
  • Pembrolizumab in a phase Ib study

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.